Radiopharm Theranostics Initiates Phase 1/2a Clinical Trial for BetaBart (RV-01)

Radiopharm Theranostics has dosed the first patient in its Phase 1/2a clinical trial of 177Lu-Betabart (RV-01), a Lu177-tagged engineered monoclonal antibody targeting B7-H3. The trial aims to evaluate safety, biodistribution, and radiation dosimetry, as well as preliminary anti-tumor activity. Preclinical studies have shown tumor shrinkage and prolonged survival. The agent was developed by Radiopharm Ventures, a joint venture between Radiopharm and MD Anderson Cancer Center.